Elevated expression of PTCD3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer

Huang,Yiqiao; Jiang,Ganggang; Liang,Xue; Lan,Ziquan; Su,Zhengming; Wu,Hualing; Weng,Jinsheng; Jiang,Xianhan

doi:10.3892/mmr.2018.9402

Elevated expression of PTCD3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer

Authors:
- Yiqiao Huang
- Ganggang Jiang
- Xue Liang
- Ziquan Lan
- Zhengming Su
- Hualing Wu
- Jinsheng Weng
- Xianhan Jiang
View Affiliations

Affiliations: Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China, Department of Central Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510700, P.R. China
Published online on: August 20, 2018 https://doi.org/10.3892/mmr.2018.9402
Pages: 3914-3922
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pentatricopeptide repeat domain protein 3 (PTCD3) is a mitochondrial RNA‑binding protein that serves a role in mitochondrial translation. PTCD3 was originally reported as an oncogene that is involved in breast cancer and lymphoma. However, the expression and function of PTCD3 in prostate cancer (PCa) are unknown. Therefore, the aim of the present study was to investigate the expression of PTCD3 and its clinical significance in PCa. Immunohistochemistry and dataset analyses revealed that PTCD3 protein expression levels were enhanced in human PCa tissues and mouse PCa models. PTCD3 expression levels were positively correlated with advanced PCa pathological grade and clinical stage. Additionally, PTCD3 mRNA expression was positively correlated with tissue malignancy, high Gleason score and distant metastasis in The Cancer Genome Atlas dataset. Kaplan‑Meier analysis revealed that high PTCD3 levels can predict the increased biochemical recurrence (BCR)‑free survival in all patients with or without metastasis. The overexpression of PTCD3 could be used as an independent prognostic marker of poor BCR‑free survival. Immunofluorescence and western blot analysis in human PCa cell lines further confirmed that PTCD3 levels were associated with the hormone independence of PCa. Therefore, the present study revealed that PTCD3 levels may serve as a novel biomarker for PCa prognosis.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Society AC: Cancer facts & figures 2016. American Cancer Society; Atlanta, GA: 2016
3	Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O and Bray F: International variation in prostate cancer incidence and mortality rates. Eur Urol. 61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
4	Blute ML Jr, Damaschke NA and Jarrard DF: The epigenetics of prostate cancer diagnosis and prognosis: Update on clinical applications. Curr Opin Urol. 25:83–88. 2015. View Article : Google Scholar : PubMed/NCBI
5	Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E and de Koning H: Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J Natl Cancer Inst. 101:374–383. 2009. View Article : Google Scholar : PubMed/NCBI
6	PSA-based screening for prostate cancer, . Too many adverse effects. Prescrire Int. 21:215–217. 2012.PubMed/NCBI
7	Garg AD, Martin S, Golab J and Agostinis P: Danger signalling during cancer cell death: Origins, plasticity and regulation. Cell Death Differ. 21:26–38. 2014. View Article : Google Scholar : PubMed/NCBI
8	Sehrawat A, Roy R, Pore SK, Hahm ER, Samanta SK, Singh KB, Kim SH, Singh K and Singh SV: Mitochondrial dysfunction in cancer chemoprevention by phytochemicals from dietary and medicinal plants. Semin Cancer Biol. 47:147–153. 2017. View Article : Google Scholar : PubMed/NCBI
9	Guerra F, Guaragnella N, Arbini AA, Bucci C, Giannattasio S and Moro L: Mitochondrial dysfunction: A novel potential driver of epithelial-to-mesenchymal transition in cancer. Front Oncol. 7:2952017. View Article : Google Scholar : PubMed/NCBI
10	Ježek J, Cooper KF and Strich R: Reactive oxygen species and mitochondrial dynamics: The yin and yang of mitochondrial dysfunction and cancer progression. Antioxidants (Basel). 7(pii): E132018. View Article : Google Scholar : PubMed/NCBI
11	Jiang X, Zhong W, Huang H, He H, Jiang F, Chen Y, Yue F, Zou J, Li X, He Y, et al: Autophagy defects suggested by low levels of autophagy activator MAP1S and high levels of autophagy inhibitor LRPPRC predict poor prognosis of prostate cancer patients. Mol Carcinog. 54:1194–1204. 2015. View Article : Google Scholar : PubMed/NCBI
12	Jiang X, Li X, Huang H, Jiang F, Lin Z, He H, Chen Y, Yue F, Zou J, He Y, et al: Elevated levels of mitochondrion-associated autophagy inhibitor LRPPRC are associated with poor prognosis in patients with prostate cancer. Cancer. 120:1228–1236. 2014. View Article : Google Scholar : PubMed/NCBI
13	Li Y, Beckman KB, Caberto C, Kazma R, Lum-Jones A, Haiman CA, Le Marchand L, Stram DO, Saxena R and Cheng I: Association of genes, pathways, and haplogroups of the mitochondrial genome with the risk of colorectal cancer: The multiethnic cohort. PLoS One. 10:e01367962015. View Article : Google Scholar : PubMed/NCBI
14	Burch TC, Rhim JS and Nyalwidhe JO: Novel altered mitochondrial genes in prostate cancer progression. Cancer Res. 75:2015. View Article : Google Scholar
15	Genecards: Summaries for PTCD3 Gene. https://www.genecards.org/cgi-bin/carddisp.pl?gene=PTCD3August 8–2018
16	Lightowlers RN and Chrzanowska-Lightowlers ZM: Human pentatricopeptide proteins: Only a few and what do they do? RNA Biol. 10:1433–1438. 2013. View Article : Google Scholar : PubMed/NCBI
17	Rackham O, Davies SM, Shearwood AM, Hamilton KL, Whelan J and Filipovska A: Pentatricopeptide repeat domain protein 1 lowers the levels of mitochondrial leucine tRNAs in cells. Nucleic Acids Res. 37:5859–5867. 2009. View Article : Google Scholar : PubMed/NCBI
18	Madhavan S, Gusev Y, Singh S and Riggins RB: ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer. J Exp Clin Cancer Res. 34:452015. View Article : Google Scholar : PubMed/NCBI
19	D'Andrea A, Gritti I, Nicoli P, Giorgio M, Doni M, Conti A, Bianchi V, Casoli L, Sabò A, Mironov A, et al: The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas. Oncotarget. 7:72415–72430. 2016.PubMed/NCBI
20	Cancer Genome Atlas Research Network, . Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
21	Esfahani M, Ataei N and Panjehpour M: Biomarkers for evaluation of prostate cancer prognosis. Asian Pac J Cancer Prev. 16:2601–2611. 2015. View Article : Google Scholar : PubMed/NCBI
22	Baade PD, Youlden DR and Krnjacki LJ: International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res. 53:171–184. 2009. View Article : Google Scholar : PubMed/NCBI
23	Manna S: An overview of pentatricopeptide repeat proteins and their applications. Biochimie. 113:93–99. 2015. View Article : Google Scholar : PubMed/NCBI
24	Baggio F, Bratic A, Mourier A, Kauppila TE, Tain LS, Kukat C, Habermann B, Partridge L and Larsson NG: Drosophila melanogaster LRPPRC2 is involved in coordination of mitochondrial translation. Nucleic Acids Res. 42:13920–13938. 2014. View Article : Google Scholar : PubMed/NCBI
25	Pavlova NN and Thompson CB: The emerging hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016. View Article : Google Scholar : PubMed/NCBI
26	Zong WX, Rabinowitz JD and White E: Mitochondria and cancer. Mol Cell. 61:667–676. 2016. View Article : Google Scholar : PubMed/NCBI
27	Oran AR, Adams CM, Zhang XY, Gennaro VJ, Pfeiffer HK, Mellert HS, Seidel HE, Mascioli K, Kaplan J, Gaballa MR, et al: Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer. Oncotarget. 7:72395–72414. 2016. View Article : Google Scholar : PubMed/NCBI